Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
This study aims to see if a 12-week exercise program designed to reduce long periods of inactivity is feasible in newly diagnosed lymphoma participants receiving R-CHOP or POLA-R-CHP chemotherapy treatments, and whether it can improve heart health and reduce chemotherapy drug side effects.
• Ability to understand and the willingness to sign informed consent prior to any study- related procedures.
• Patients diagnosed with lymphoma.
• Will receive first line R-CHOP or POLA-R-CHP chemotherapy regimens, patients do not need to be within a certain timeframe from diagnosis.
• Aged ≥18 years; due to the rarity of the disease in those \<18 years, this age bracket will not be included.
• Engaging in ≤60-minutes of structured moderate or vigorous intensity exercise.
• Have physician clearance to participate in exercise.
• Speak English.
• Willing to travel to Dana-Farber Cancer Institute for necessary data collection and exercise sessions.
• Access to a phone that can receive text messages.